Market Place
Sourcing Support
Merck plans to launch US subcutaneous version of Keytruda
28 Mar 2025 //
REUTERS
Actinium Pharmaceuticals Business Update After Mar-A-Lago Present
27 Mar 2025 //
PR NEWSWIRE
Mural Updates Ph III Nemvaleukin, Keytruda Trial In Ovarian Cancer
25 Mar 2025 //
GLOBENEWSWIRE
First Patient Dosed In Immutep’s Ph III NSCLC Trial
25 Mar 2025 //
GLOBENEWSWIRE
Evaxion to unveil phase 2 data for cancer vaccine at AACR Meeting
25 Mar 2025 //
GLOBENEWSWIRE
BioInvent`s BI-1808 antibody featured at T-Cell Lymphoma Forum
21 Mar 2025 //
ACCESSWIRE
BioInvent gets FDA Orphan Drug Designation for BI-1808 for T-cell
20 Mar 2025 //
ACCESSWIRE
Merck`s Biologic Keytruda Receives Approval in US
19 Mar 2025 //
FDA
BioCity, MSD Partner To Evaluate BC3195 + Keytruda In Solid Tumors
13 Mar 2025 //
PR NEWSWIRE
Merck’s Injectable Keytruda Create Legal Dispute With Halozyme
06 Mar 2025 //
BIOSPACE
Innovent Doses First Patient in IBI363 Melanoma Pivotal Study
03 Mar 2025 //
PR NEWSWIRE
Microbiotica Shares MB097 Data in Advanced Melanoma
26 Feb 2025 //
PHARMAWEB
Merck expects Keytruda to be part of government price
26 Feb 2025 //
REUTERS
Medicenna Reports MDNA11’s Anti-Cancer Activity at AACR Conference
25 Feb 2025 //
GLOBENEWSWIRE
FDA Grants Review To Merck’s Keytruda Combo For Head & Neck Cancer
25 Feb 2025 //
BUSINESSWIRE
Ignite Proteomics To Present MHC-II Data On Pembrolizumab Response
24 Feb 2025 //
GLOBENEWSWIRE
Bicara Begins Ph2/3 Ficerafusp Alfa Trial In Head, Neck Cancer
11 Feb 2025 //
GLOBENEWSWIRE
Pfizer & Astellas Padcev + Keytruda Shows Efficacy in Cancer
10 Feb 2025 //
BUSINESSWIRE
Pyxis Oncology Starts PYX-201 Combination and Monotherapy Trials
04 Feb 2025 //
GLOBENEWSWIRE
Adagene Updates Muzastotug, Keytruda Data In Colorectal Cancer
27 Jan 2025 //
GLOBENEWSWIRE
Merck, Eisai combo misses survival goal in GI cancer trial
25 Jan 2025 //
FIERCE PHARMA
Adagene To Present Muzastotug Data With Keytruda At GI Symposium
21 Jan 2025 //
GLOBENEWSWIRE
China`s NMPA Approves Padcev + Keytruda for Advanced Bladder Cancer
08 Jan 2025 //
PR NEWSWIRE
Merck’s KEYTRUDA® Approved in China for NSCLC Neoadjuvant Treatment
16 Dec 2024 //
BUSINESSWIRE
Merck`s Biologic Keytruda Receives Suppl Approval in US
11 Dec 2024 //
FDA
BioNTech posts overall survival data on would-be Keytruda killer
11 Dec 2024 //
FIERCE BIOTECH
Ideaya Starts Phase 1 Trial For IDE161 With KEYTRUDA® In Cancer
10 Dec 2024 //
PR NEWSWIRE
Merck Announces Ph 3 KEYLYNK-001 Trial Success in Ovarian Cancer
09 Dec 2024 //
BUSINESSWIRE
Medicenna Announces Complete Response in Study with KEYTRUDA®
05 Dec 2024 //
GLOBENEWSWIRE
Merck Sharp`s Biologic Keytruda Receives Suppl Approval in US
20 Nov 2024 //
FDA
Merck says Keytruda injection on par with approved IV version in trial
20 Nov 2024 //
FIERCE PHARMA
Toragen Updates Data from Ph 1 Trial of TGN-S11 in HPV Cancers
18 Nov 2024 //
BUSINESSWIRE
Merck Receives CHMP Opinion for KEYTRUDA® in MPM
15 Nov 2024 //
BUSINESSWIRE
Citius Pharma Announces Promising Pembrolizumab Trial Results
11 Nov 2024 //
PR NEWSWIRE
Medicenna Announces Positive MDNA11 Data with KEYTRUDA® at SITC
11 Nov 2024 //
GLOBENEWSWIRE
BeyondSpring Presents Phase 2 Efficacy of Pembrolizumab Combo
11 Nov 2024 //
GLOBENEWSWIRE
Hookipa Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
11 Nov 2024 //
GLOBENEWSWIRE
Compugen to Present COM701, COM902 + Pembrolizumab Data at SITC
05 Nov 2024 //
PR NEWSWIRE
Akeso Enrolls First Patient in Phase 3 HNSCC Trial with Ivonescimab
30 Oct 2024 //
PR NEWSWIRE
Merck, Moderna Launch Phase 3 Trial for NSCLC Treatment
28 Oct 2024 //
BUSINESSWIRE
Merck’s KEYTRUDA® Receives New Approvals For Gynecologic Cancers
24 Oct 2024 //
BUSINESSWIRE
Exelixis And Merck Sign Clinical Development Collaboration
14 Oct 2024 //
BUSINESSWIRE
Merck`s Keytruda stages comeback in head and neck cancer
08 Oct 2024 //
FIERCE PHARMA
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
04 Oct 2024 //
FIERCE PHARMA
ABL Bio Announces Clinical Collaboration For ABL103 with Keytruda
04 Oct 2024 //
PR NEWSWIRE
Cue Biopharma Announces Presentations At SITC Annual Meeting
04 Oct 2024 //
GLOBENEWSWIRE
Merus Doses First Patient In Ph 3 Trial Of Petosemtamab
30 Sep 2024 //
GLOBENEWSWIRE
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
26 Sep 2024 //
PRESS RELEASE
Merck`s KEYTRUDA Approved In Japan For NSCLC And Carcinoma
25 Sep 2024 //
BUSINESSWIRE
Japan Approves PADCEV With KEYTRUDA For Urothelial Cancer
24 Sep 2024 //
PR NEWSWIRE
Merck Receives Positive EU CHMP Opinions for KEYTRUDA
20 Sep 2024 //
BUSINESSWIRE
FDA Approves KEYTRUDA Plus Pemetrexed Combo For Mesothelioma
18 Sep 2024 //
BUSINESSWIRE
New Efti Combination Data To Be Presented For Sarcoma
18 Sep 2024 //
GLOBENEWSWIRE
Antennova`s CD73 Inhibitor Shows 89.5% DCR At ESMO 2024
17 Sep 2024 //
PR NEWSWIRE
PESG Reports On Nuvectis Pharma`s NXP900
16 Sep 2024 //
BUSINESSWIRE
PDS Biotech Announces VERSATILE-002 Results At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
NextCure Presented NC410 Phase 1b Results At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Keytruda Plus Chemo Reduces Death Risk In Early Breast Cancer
15 Sep 2024 //
BUSINESSWIRE
Keytruda Shows Survival Win In Early Triple-Negative Breast Cancer
15 Sep 2024 //
FIERCE PHARMA
Merck`s KEYTRUDA Demonstrates 10-Year Survival Benefit In Melanoma
15 Sep 2024 //
BUSINESSWIRE
